Shaikh Naazli M, Manche Edward E
Stanford University School of Medicine, Stanford, California 94305, USA.
J Cataract Refract Surg. 2002 Mar;28(3):485-90. doi: 10.1016/s0886-3350(01)01287-1.
To evaluate the safety, efficacy, predictability, and visual results of laser in situ keratomileusis (LASIK) using the Bausch & Lomb Technolas(R) 217 scanning-spot laser for the treatment of myopia and compound myopic astigmatism.
Stanford Eye Laser Center, Stanford, California, USA.
In a prospective study, 110 eyes of 58 patients with a mean spherical equivalent (SE) of -4.87 diopters (D) +/- 2.5 (SD) (range -1.0 to -11.4 D) had LASIK for myopia and compound myopic astigmatism using the Technolas 217 scanning-spot laser. The primary outcome variables included preoperative and postoperative best spectacle-corrected visual acuity (BSCVA), uncorrected visual acuity (UCVA), achieved versus attempted correction, vector analysis of astigmatism, and complications.
One hundred ten eyes were available for analysis at 3 months. The mean SE refraction was reduced 95% (mean -0.23 +/- 0.4 D), and astigmatism was reduced 70% (mean 0.28 +/- 0.3 D). One day postoperatively, 100% of eyes had a UCVA of 20/40 or better, 96% had 20/25 or better, 77% had 20/20 or better, and 39% had 20/15 or better. At the 3-month examination, 100% of eyes had a UCVA of 20/40 or better, 95% had 20/25 or better, 83% had 20/20 or better, and 48% had 20/15 or better. Ninety percent of eyes were within +/-0.5 D of emmetropia. No eye lost 2 or more lines of BSCVA.
The Technolas 217 scanning-spot laser produced excellent postoperative UCVA and BSCVA. It was predictable, safe, and effective for the treatment of myopia and compound myopic astigmatism. Long-term follow-up is needed to assess the stability of the procedure.
使用博士伦Technolas(R) 217扫描点激光评估准分子原位角膜磨镶术（LASIK）治疗近视和复合性近视散光的安全性、有效性、可预测性及视觉效果。
美国加利福尼亚州斯坦福市斯坦福眼科激光中心。
在一项前瞻性研究中，58例患者的110只眼平均等效球镜度（SE）为-4.87屈光度（D）±2.5（标准差）（范围-1.0至-11.4 D），使用Technolas 217扫描点激光进行LASIK治疗近视和复合性近视散光。主要观察变量包括术前和术后最佳矫正视力（BSCVA）、裸眼视力（UCVA）、实际矫正与预期矫正情况、散光矢量分析及并发症。
3个月时110只眼可进行分析。平均SE屈光度降低95%（平均-0.23±0.4 D），散光降低70%（平均0.28±0.3 D）。术后1天，100%的眼UCVA为20/40或更好，96%为20/25或更好，77%为20/20或更好，39%为20/15或更好。在3个月检查时，100%的眼UCVA为20/40或更好，95%为20/25或更好，83%为20/20或更好，48%为20/15或更好。90%的眼屈光不正度数在正视眼±0.5 D范围内。没有眼的BSCVA下降2行或更多。
Technolas 217扫描点激光术后产生了优异的UCVA和BSCVA。它在治疗近视和复合性近视散光方面具有可预测性、安全性和有效性。需要长期随访以评估该手术的稳定性。
